SCHEMBL4715904

SCHEMBL4715904

O=c1ccc2c(ccn2Cc2cccnc2)n1-c1ccccc1

nearest known ligand 0.46

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
POLB P06746 1/20 0.46
DHPS P49366 1/20 0.43
CHRM1 P11229 1/20 0.42
ALDH1A1 P00352 1/20 0.42
ALOX5 P09917 1/20 0.41
PDE7A Q13946 1/20 0.41
NOX4 Q9NPH5 2/20 0.40
CYBB P04839 1/20 0.40
OPRM1 P35372 1/20 0.40
OPRD1 P41143 1/20 0.40
OPRK1 P41145 1/20 0.40
OPRL1 P41146 1/20 0.40
GABRA1 P14867 1/20 0.40
GABRA5 P31644 1/20 0.40
LMNA P02545 1/20 0.40
CYP11B1 P15538 1/20 0.40
KDM4E B2RXH2 1/20 0.39
L3MBTL1 Q9Y468 1/20 0.39
KDM4C Q9H3R0 1/20 0.39
BRD4 O60885 1/20 0.39

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL4713845 0.87 BRD4 (0.46) ALDH1A1KDM4EBRD4
SCHEMBL5113137 0.86 HTR6 (0.44) ALDH1A1PDE7AOPRL1LMNAKDM4E
SCHEMBL4714110 0.79 LMNA (0.44) POLBALDH1A1LMNACYP11B1KDM4E
SCHEMBL5124227 0.78 SMN1; SMN2 (0.43) ALDH1A1LMNACYP11B1KDM4EL3MBTL1
SCHEMBL4715873 0.78 TP53 (0.46) POLBALDH1A1LMNACYP11B1KDM4E
SCHEMBL4716315 0.78 ALDH1A1 (0.47) POLBALDH1A1LMNAKDM4E
SCHEMBL4713858 0.78 MAPT (0.46) POLBALDH1A1LMNACYP11B1KDM4E
SCHEMBL5124881 0.76 GSK3A (0.39) POLBALDH1A1LMNAL3MBTL1
SCHEMBL4714450 0.75 RGS4 (0.46) CHRM1ALDH1A1LMNAKDM4EL3MBTL1
SCHEMBL4761608 0.75 MAPT (0.36) POLBALDH1A1LMNAL3MBTL1BRD4

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-7456286-B2 Bicyclic heteroaromatic compounds as kinase inhibitors UCB PHARMA, S.A. (BE) 2008-11-25 US claimed
US-20060122212-A1 Bicyclic heteroaromatic compounds as kinase inhibitors CELLTECH R&D LIMITED (GB) 2006-06-08 US claimed
US-7456286-B2 Bicyclic heteroaromatic compounds as kinase inhibitors UCB PHARMA, S.A. (BE) 2008-11-25 US disclosed
EP-1549648-B1 BICYCLIC HETEROAROMATIC COMPOUNDS AS KINASE INHIBITORS UCB PHARMA SA (BE) 2008-11-12 EP disclosed
US-20060122212-A1 Bicyclic heteroaromatic compounds as kinase inhibitors CELLTECH R&D LIMITED (GB) 2006-06-08 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20060122212-A1 Bicyclic heteroaromatic compounds as kinase inhibitors MAP2K2, MAP2K7, MAP2K3 POLB 964/4885DHPS 2276/4885CHRM1 4363/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.